Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors

NCT01748149 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01748149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01748149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Completed
Start date
April 29, 2014
Completion date
July 31, 2025
Enrollment
40 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric recurrent/refractory brafv600e-mutant gliomas